Abstract: Alzheimer’s disease (AD) is a common neurodegenerative disorder and the leading cause of dementia. It has been estimated that over 50 million people worldwide were affected by dementia in 2019, and the prevalence of dementia is expected to double approximately once every 20 years (Govindpani et al., 2017). Most people who die with AD require high levels of care for long periods of time. The underlying causes of AD are not well understood, and there are no current treatments preventing the onset or delaying the progression of the disease. Several decades of intensive research have yielded a range of drugs that alter the metabolism of amyloid-β (Aβ) and tau protein levels, the main components of the aggregates found in the brains of people with AD. Numerous therapeutic approaches that target the production, toxicity, and removal of Aβ and tau protein are being developed, but these have yet to fulfill expectations in clinical trials. A large number of major failed trials are alarming to the AD community of researchers and affected families. Therefore, there is an urgent need to discover ways to improve and restore memory function and find better and more effective ways to care for people with AD.